This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Mainstream media has begun to illustrate just how effective medical marijuana can be in helping cancer patients. As the skin absorbs the pain-relieving compounds, the pain is blocked, but without affecting other parts of your body. Newsweek Magazine labeled marijuana the “wonder drug when it comes to the horrors of chemo.”
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinicaltrial agreement with Altasciences Company, Inc., Media: Laura Radocaj. Chipman, CPA. Chief Financial Officer. Investor Relations: Betsy Brod.
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. Pro-cannabis charities for individuals suffering debilitating illnesses have also reacted angrily.
. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinicaltrials.” and three international patents that have been issued to protect therapeutic mixtures for Parkinson’s disease, chronicpain, hyperinflammation, and heart disease.
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Tree of Knowledge will be introducing chronicpain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinicaltrials and research that will include the usage of specific strains of cannabis that aid in chronicpain and cancer treatments.
The Company’s second drug platform, Supera-CBD , is being developed to treat chronicpain, addiction and epilepsy. Media: media@mymd.com. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. Investor: Robert Schatz. 646) 421-9523.
Supera-CBD is currently on a path toward human clinicaltrials as a therapy for epilepsy, followed by chronicpain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronicpain, addiction and epilepsy. Media Contact: media@mymd.com. About MyMD Pharmaceuticals, Inc.
Studies have shown the efficacy of medical cannabis in treating conditions such as chronicpain, epilepsy, and certain mental health disorders. One significant factor is the recognition of the opioid crisis and the need for alternative pain management strategies.
1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products. Chronic or arthritic pain.”. Chronicpain.
It’s when presented with personal stories like that of the Rhodes family and the stream of alarming data that the significance of Tetra Bio-Pharma’s (TBP) clinicaltrials is worth exploring. “The data also indicate that fentanyl and other fentanyl-related substances continue to be a major driver of this crisis,” Health Canadanotes.
The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. Media: Laura Radocaj. In October 2021, Virpax announced that a $1.87 Christopher M. Betsy Brod.
Upon completion of all the required IND enabling studies and subsequent review by the FDA, Virpax intends to conduct a Phase 1 study to evaluate the relative bioavailability and pharmacokinetics of Epoladerm™ Virpax recently announced the execution of a clinicaltrial agreement with Altasciences Company, Inc., Chipman, CPA.
The constant distractions, notifications, and social media outrages of the day can also boost your anxiety and stress, and make it much harder to just live in the moment. Both THC and CBD rich products may help those suffering from pain lasting several months.
The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.
Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. This article analyses media representations of medicinal cannabis in Australian medical publications. Media framing of cannabis.
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.
That there’s not enough information about, there’s not enough clinicaltrials, and there’s not enough this and that. They get pumped out through the media and everybody’s talking about how dangerous it is. But really, what we’re talking about is, individuals who are chronically using cannabis and we’re not distinguishing.
MEDICAL MARIJUANA FOR VETS Could veterans suffering from PTSD or chronicpain be able to use cannabis to relieve their symptoms? The company is the first social media platform to permit such ads , and they come with many restrictions on type of content. We have an update on those SAFE Banking talks.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content